HEALTH● LOWSep 16 · Sep 16, 2026, 1:21 PM
Novartis scraps ALS therapy after mid-stage trial setback
Seeking Alpha Tech · global
Novartis has discontinued its ALS therapy development after a setback in mid-stage trials. This decision impacts potential future treatments for Amyotrophic Lateral Sclerosis.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH28m agoHealth Minister rules out withdrawal of hospital billing transparency orderThe HinduHEALTH41m agoEli Lilly's Omvoh boosted by new ulcerative colitis, Crohn's dataSeeking Alpha TechHEALTH48m agoCanadians Overwhelmingly Support a Smoke - Free Generation Law , a New Poll Commissioned by National Lung Health Alliance Findssimcoereformer.ca · CanadaHEALTH1h agoToluwanisings was rushed to 8 hospitals before death – PAVanguard Nigeria